Can I get it?
Not for this use. CJC-1295 has no EU authorisation for it, so it cannot be prescribed or dispensed here for that purpose.
Why buying it online is risky
CJC-1295 · Eindhoven
CJC-1295 in Eindhoven.
Not something we can prescribe. Our doctors can review your case for an EU-approved treatment instead.
Full refund if a review is not approved
NOT AVAILABLE TODAY
Hi-Doctor does not prescribe CJC-1295.
Our licensed doctors currently focus on three areas with solid clinical evidence and a clear EU regulatory framework. We extend the catalogue as specialists join and regulation allows. CJC-1295 is outside the current scope.
Buying CJC-1295 online without a valid prescription carries counterfeiting and toxicity risks. Always consult a licensed healthcare professional.
IN PLAIN TERMS
What CJC-1295 is, and how to get treatment
CJC-1295 is a laboratory-made copy of growth-hormone-releasing hormone, altered so that it stays active in the blood for much longer than the natural hormone, which makes the pituitary gland release more of the body's own growth hormone. It has never been approved as a medicine in the European Union or anywhere else, and no doctor can prescribe it; the one registered company trial, in people with HIV-related abdominal fat, was stopped without results. Regulators have recorded serious adverse events with it, including raised heart rate and a whole-body flushing reaction. What is sold online is a research chemical made outside medicines manufacturing rules, so its strength, purity and contents cannot be verified.
CJC-1295 has no EU marketing authorisation for this use. It may be an approved medicine for something else, or approved in another country — but not something a doctor here can prescribe for this.
What can I take instead?
Our doctors review every option and recommend what fits your history and goals.
What do the studies show?
Every trial behind CJC-1295 is listed below with how many people took part and whether the results are peer-reviewed or a company announcement.
Jump to the studiesWHAT WE DO COVER
If your question fits one of these three areas, a licensed doctor reviews it in less than 2 hours on average for €35.
TREATMENTS
Three categories, one process.
Choose what fits. The journey is identical.
ONGOING PLANWeight loss
A medical consultation on your weight goal. Treatment if appropriate.
€25/month28-day treatment cycle
Explore weight lossONE-OFFSexual health
An absolutely discreet consultation for intimate concerns.
€35 one-offFull refund if not approved
Explore sexual healthONGOING PLANHair growth
Medical assessment and tailored treatment for hair loss.
€15/monthBilled €45 every 90 days
Explore hair growthLicensed EU doctors
Doctor review in less than 2 hours on average
50,000+ patients served
Secure patient account
VERIFIED EVIDENCE
CJC-1295: evidence and regulatory guide.
WHAT IT IS
How it works
A laboratory-made copy of growth-hormone-releasing hormone, chemically modified so it stays in the blood far longer than the natural hormone; it acts on the pituitary gland's GHRH receptor to increase release of the body's own growth hormone.
- GHRH receptor (GHRHR)
DEVELOPMENT STAGE
Not marketed in the EU
Sources
Last reviewed 2026-07-27
- FDA — Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (CJC-1295 entry; page current as of 22 April 2026)
- ClinicalTrials.gov — NCT00267527, phase 2 study of CJC-1295 in HIV-associated visceral obesity (ConjuChem); terminated, no results posted
- The emerging landscape of performance-enhancing peptides modulating the GH-IGF1 axis — Front Endocrinol 2026;17:1822475
- EMA — medicines database (no authorised EU medicine contains CJC-1295; checked against the EMA medicine list generated 27 July 2026)
NAMED SAFETY SIGNALS
What has been reported with CJC-1295.
Serious adverse events identified by the FDA
The US Food and Drug Administration states it "has identified serious adverse events associated with CJC-1295 including increased heart rate and systemic vasodilatory reaction", and that "available clinical data are limited".
Impurity and immunogenicity risk
The FDA notes preparations "may pose risk for immunogenicity for certain routes of administration and may have complexities with regard to peptide-related impurities and API characterization".
Its only registered company trial was stopped
A phase 2 trial in people with HIV-associated visceral obesity (NCT00267527, ConjuChem) was terminated and no results were posted. No completed trial has reported that CJC-1295 is safe or effective for any use.
Unregulated supply
Sold online as a research chemical outside medicines manufacturing rules, so strength, purity and contents are unverifiable.
UNAPPROVED PRODUCTS ONLINE
Why buying CJC-1295 online is not a shortcut.
No doctor in the EU can prescribe it for this use — including ours. It may be authorised in another country, or for a different condition.
Check the EU common logo
A legitimate online pharmacy in the EU must display the common logo linked to its national register. The logo is a verification check; it cannot make an unapproved medicine legal.
How the EU common logo worksHOW IT WORKS · 5 STEPS
Five steps. No waiting room.
From the online consultation to ongoing follow-up — without leaving home.
- 5 minutes
Start your online visit
Answer a 5-minute health questionnaire from home.
- Less than 2 hours
A doctor reviews your case
A licensed doctor reviews your answers and replies personally.
- Refund guarantee
Review and payment
If not approved, we refund your €35 one-off in full.
- EU pharmacies
Collect treatment from the pharmacy
Collect it at any EU pharmacy with your e-prescription.
- 4-week check-in
Ongoing support
Private chat, 4-week check-in, simple prescription renewal.
NOTIFY ME
We'll tell you when we add new treatments.
We only use your email for this notification. You can opt out at any time.
FREQUENTLY ASKED QUESTIONS